• Google

    Arbutus Biopharma (NASDAQ:ABUS) Upgraded by Wedbush to Neutral /Link

    Arbutus Biopharma (NASDAQ:ABUS) was upgraded by research analysts at Wedbush from an “underperform” rating to a “neutral” rating in a note issued to investors on Monday, October 15th, Marketbeat reports. The brokerage currently has a $5.00 target price on the biopharmaceutical company’s stock. Wedbush’s price target would indicate a potential upside of 15.47% from the […]

    (@)Vince Mercandetti

    Published on 23 Oct 2018 at 04:04PM

    Analyst Recommendations for Arbutus Biopharma (NASDAQ:ABUS) Abbott Laboratories  is Somerville Kurt F’s 8th Largest Position Amy E. Weaver Sells 5,325 Shares of salesforce.com, inc.  Stock Somerville Kurt F Sells 43,485 Shares of Oracle Co. Sumitomo Mitsui Asset Management Company LTD Raises Holdings in 3M Co Foamix Pharmaceuticals Ltd  Given Consensus Recommendation of “Hold” by Analysts Web Analytics share news on Facebook tweet this investment news share on linkedin share on StockTwits share on Google Plus share on reddit

  • Recent Posts